T cell-redirecting therapies (TCRTs), such as chimeric antigen receptor (CAR) or T cell receptor (TCR) T cells and T cell engagers, have emerged as a highly effective treatment modality, particularly in the B and plasma cell-malignancy setting. However, many patients fail to achieve deep and durable responses; while the lack of truly unique tumor antigens, and concurrent on-target/off-tumor toxicities, have hindered the development of TCRTs for many other cancers. In this review, we discuss the recent developments in TCRT targets for hematological malignancies, as well as novel targeting strategies that aim to address these, and other, challenges.

中文翻译：

---

血液恶性肿瘤中的 T 细胞重定向疗法：改善靶向性的最新进展和新策略


T 细胞重定向疗法 (TCRT)，例如嵌合抗原受体 (CAR) 或 T 细胞受体 (TCR) T 细胞和 T 细胞接合剂，已成为一种高效的治疗方式，特别是在 B 细胞和浆细胞恶性肿瘤环境中。然而，许多患者未能获得深度且持久的缓解；而缺乏真正独特的肿瘤抗原，以及同时存在的靶向/脱瘤毒性，阻碍了许多其他癌症的 TCRT 的发展。在这篇综述中，我们讨论了血液恶性肿瘤 TCRT 靶点的最新进展，以及旨在解决这些和其他挑战的新颖靶向策略。